NCT06725225Not yet recruiting
Machine Learning for Predicting and Managing Quality of Life in Lung Cancer Immunotherapy Patients
Development of a Machine Learning-Based Risk Prediction Model and Stratified Management Strategies for Quality of Life in Lung Cancer Patients Undergoing Immunotherapy
Source: ClinicalTrials.gov · Last updated 13 Dec 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The goal of this study is to explore whether health-related quality of life (HRQoL) can be used as a predictive indicator for lung cancer patients and to implement clinical interventions. The study addresses two main objectives: Analyzing HRQoL data of lung cancer patients undergoing immunotherapy using machine learning clustering methods to explore data patterns and build an HRQoL early warning model (already developed). Validating this HRQoL early warning model in real-world settings by classifying patients with different HRQoL characteristics and assessing the clinical value of the model
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 200 (estimated)
- First submitted
- 1 Dec 2024
- Start date
- 1 Jan 2025
- Primary completion date
- 1 Dec 2025
- Lead sponsor
- Second Affiliated Hospital of Zunyi Medical University
- Diseases
- Lung cancer
- NCT number
- NCT06725225
What you commit to
- Study type: Interventional
- Planned participants: 200
- From 1 Jan 2025 to the primary completion date, 1 Dec 2025
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Cognitive impairment or mental illness
- Other severe diseases
Who the study is looking for
- Histologically diagnosed with lung cancer
- Age over 18 years
- Currently receiving immunotherapy for lung cancer
- Good verbal communication ability
- Informed consent signed by the patient or family member
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.